Skip to content

Scholar Rock SRRK Cash & Equivalents

Cash & Equivalents at other companies

Biogen logo
BiogenBIIB
$3.38B+30.2%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$33.21M-33.5%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$833.99M-43.7%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$753.1M+59.5%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$755.86M+30.2%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$241.21M+91.4%

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's cash & equivalents?
Scholar Rock (SRRK) reported cash & equivalents of $430.54M in Q1 2026.
How has Scholar Rock's cash & equivalents changed year-over-year?
Scholar Rock's cash & equivalents increased by 212.2% year-over-year, from $137.93M to $430.54M.
What is the long-term trend for Scholar Rock's cash & equivalents?
Over 5 years (2020 to 2025), Scholar Rock's cash & equivalents has grown at a 15.1% compound annual growth rate (CAGR), from $160.36M to $323.53M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.